Viewing Study NCT00880269

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:08 PM
Ignite Modification Date: 2026-02-20 @ 10:46 PM
Study NCT ID: NCT00880269
Status: COMPLETED
Last Update Posted: 2017-02-23
First Post: 2009-03-30
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Refractory Leukemia View
None Acute Myelogenous Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute myeloid leukemia View
None AML View
None relapsed acute myeloid leukemia View
None refractory AML View
None refractory de novo AML View
None refractory secondary AML View
None secondary AML View
None AML following myelodysplastic syndrome (MDS) View
None AML following antecedent hematological disorder (AHD) View
None AML resistant to therapy View